Multidisciplinary Management of Hepatocellular Carcinoma in Clinical Practice

Abstract EN

Background.

Hepatocellular carcinoma (HCC) patients require different treatment strategies according to disease extension, liver function, and patient’s fitness.

We evaluated HCC multidisciplinary management in clinical practice.

Methods.

Consecutive patients were followed and treated with tailored medical, locoregional, and surgical treatments, according to disease stage and patient’s fitness (age, Cumulative Illness Rating Scale (CIRS)).

Activity, efficacy, and safety were evaluated.

Results.

Thirty-eight patients were evaluated: median age, 74; elderly 92%; CIRS secondary 28 (74%); Child-Pugh A 20 (53%), B 11 (29%); and Barcelona Clinic Liver Cancer (BCLC) 0 2 (5%), A 9 (24%), B 10 (26%), C 13 (34%), and D 4 (11%).

Overall survival (OS) was 30 months.

At 9 months median follow-up, among 25 unresectable HCC, OS was 10 months; BCLC B–D unfit for sorafenib showed OS 3 months.

Ten patients (40%) received sorafenib: Child-Pugh A 5 (50%) and B 5 (50%) and disease control rate 89%, progression-free survival 7 months, and OS 9 months.

G3-4 toxicities: anorexia, hypertransaminaemia, hyperbilirubinemia, and hypercreatininemia.

Limiting toxicity syndromes were 40%, all multiple sites.

Conclusion.

HCC patients require multidisciplinary clinical management to properly select tailored treatments according to disease stage, fitness, and liver function.

Patients suitable for sorafenib should be carefully selected, monitored for individual safety, and prevalently characterized by limiting toxicity syndromes multiple sites.